

Produktinformation



Forschungsprodukte & Biochemikalien
Zellkultur & Verbrauchsmaterial
Diagnostik & molekulare Diagnostik
Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien T. +43(0)1 489 3961-0 F. +43(0)1 489 3961-7 <u>mail@szabo-scandic.com</u> www.szabo-scandic.com

PRODUCT INFORMATION



Mizolastine

Item No. 9000566

CAS Registry No.: Formal Name:	108612-45-9 2-[[1-[1-[(4-fluorophenyl) methyl]-1H-benzimidazol-2-yl]-4- piperidinyl]methylamino]-4(3H)- pyrimidinone	F
Synonym:	SL 850324	
MF:	C ₂₄ H ₂₅ FN ₆ O	\rangle N, \models 0
FW:	432.5	
Purity:	≥98%	
UV/Vis.:	λ _{max} : 217, 289 nm	N N H
Supplied as:	A crystalline solid	
Storage:	-20°C	~
Stability:	≥2 years	
Information represents the product encodifications. Batch encodific analytical results are provided on each cartificate of analytic		

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Mizolastine is supplied as a crystalline solid. A stock solution may be made by dissolving the mizolastine in the solvent of choice, which should be purged with an inert gas. Mizolastine is soluble in the organic solvent chloroform at a concentration of approximately 10 mg/ml. Mizolastine is also slightly soluble in DMSO and dimethyl formamide.

Description

Mizolastine is a histamine H₁ receptor antagonist (K_i = 0.001 μ M).¹ It is selective for histamine H₁ over histamine H₂ and H₃ receptors (K s = >100 μ M for both), as well as the serotonin (5-HT) receptor subtypes 5-HT_{1A}, 5-HT_{1B}, 5-HT_{1C}, 5-HT_{1D}, 5-HT₂, and 5-HT₃, dopamine D₁ and D₂, α_1 - and α_2 -adrenergic, adenosine, and muscarinic receptors in radioligand binding assays (K₁s = >1 μ M for all). Mizolastine (0.1, 0.3, and 1 mg/kg) reduces histamine release from bronchial mast cells in ovalbumin-sensitized guinea pigs. It reduces histamine-induced paw edema in rats, skin edema in dogs, and bronchoconstriction in guinea pigs (ED₅₀s = 0.5, 0.07, and 0.03 mg/kg, respectively). Mizolastine also inhibits passive cutaneous anaphylaxis, as well as lethal shock induced by compound 48/80 (Item No. 22173) in rats $(ED_{50}s = 1.6 \text{ and } 0.07 \text{ mg/kg}, \text{ respectively})$. Formulations containing mizolastine have been used in the treatment of allergic rhinitis and urticaria.

Reference

1. Selve, N., Pichat, P., Goldhill, J., et al. Pharmacological profile of mizolastine, a novel histamine H₁ receptor antagonist. Mast cells and basophils. Moore, G., Lichtenstein, L.M., Galli, S.J., editors, 1st edition, Academic Press (2000).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 07/23/2020

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM